Storia in 4 fonti

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)

Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo9 h fa

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)

Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.

originale

endpoints.news14 h fa

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech up to $1.9 billion.

Leggi questa versione → originale

Timeline cronologica

mercoledì 24 giugno 2026·forbes.com
Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration
Strategic research collaboration and license agreement is worth up to $1.9 billion to Abbisko
mercoledì 24 giugno 2026·morningstar.com
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Timeline cronologica

Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Abbisko Therapeutics Deepens R&D Collaboration with Lilly

Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)